Chlojaponilactone BCAS# 1449382-91-5 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 1449382-91-5 | SDF | Download SDF |
PubChem ID | 72715021 | Appearance | Powder |
Formula | C17H18O4 | M.Wt | 286.32 |
Type of Compound | Sesquiterpenoids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
SMILES | CC1=C2C(C3C(=C)C4CC4C3(C=C2OC1=O)C)OC(=O)C | ||
Standard InChIKey | DJENQWQXZQCLHL-PVBKFEAWSA-N | ||
Standard InChI | InChI=1S/C17H18O4/c1-7-10-5-11(10)17(4)6-12-13(8(2)16(19)21-12)15(14(7)17)20-9(3)18/h6,10-11,14-15H,1,5H2,2-4H3/t10-,11-,14-,15+,17+/m1/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | 1. Chlojaponilactone B has anti-inflammatory activity, it exhibits pronounced inhibition of nitric oxide (NO) production in lipopolysaccharide (LPS)-induced RAW 264.7 macrophages. |
Targets | NO | NOS | TNF-α | IL Receptor | p65 | NF-kB | IkB | IKK |
Chlojaponilactone B Dilution Calculator
Chlojaponilactone B Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 3.4926 mL | 17.463 mL | 34.926 mL | 69.8519 mL | 87.3149 mL |
5 mM | 0.6985 mL | 3.4926 mL | 6.9852 mL | 13.9704 mL | 17.463 mL |
10 mM | 0.3493 mL | 1.7463 mL | 3.4926 mL | 6.9852 mL | 8.7315 mL |
50 mM | 0.0699 mL | 0.3493 mL | 0.6985 mL | 1.397 mL | 1.7463 mL |
100 mM | 0.0349 mL | 0.1746 mL | 0.3493 mL | 0.6985 mL | 0.8731 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- K145 hydrochloride
Catalog No.:BCC4072
CAS No.:1449240-68-9
- Senexin B
Catalog No.:BCC3990
CAS No.:1449228-40-3
- Androst-5-en-3-ol-7,17-dione acetate
Catalog No.:BCC8822
CAS No.:1449-61-2
- 24-Methylenecycloartan-3-ol
Catalog No.:BCN6254
CAS No.:1449-09-8
- 24-Methylenecycloartanone
Catalog No.:BCN7244
CAS No.:1449-08-7
- 21-Episerratenediol
Catalog No.:BCN6253
CAS No.:1449-06-5
- 18alpha-Glycyrrhetinic acid
Catalog No.:BCC8328
CAS No.:1449-05-4
- 1-Methyl-aminomethyl naphthalene
Catalog No.:BCC8471
CAS No.:14489-75-9
- ML314
Catalog No.:BCC4154
CAS No.:1448895-09-7
- MRS 2693 trisodium salt
Catalog No.:BCC7386
CAS No.:1448858-83-0
- 4',9,9'-Trihydroxy-3'-methoxy-3,7'-epoxy-4,8'-oxyneolignan
Catalog No.:BCN1563
CAS No.:144881-21-0
- Junipediol B
Catalog No.:BCN6252
CAS No.:144881-19-6
- Boeravinone O
Catalog No.:BCN6693
CAS No.:1449384-21-7
- DDR1-IN-1
Catalog No.:BCC5170
CAS No.:1449685-96-4
- DGAT1-IN-1
Catalog No.:BCC5511
CAS No.:1449779-49-0
- Pregnenolone
Catalog No.:BCN6255
CAS No.:145-13-1
- ω-Agatoxin IVA
Catalog No.:BCC7488
CAS No.:145017-83-0
- Digalactosyldiacylglycerol
Catalog No.:BCC8941
CAS No.:145033-48-3
- Fmoc-Asp(OMe)-OH
Catalog No.:BCC3090
CAS No.:145038-53-5
- FGIN-1-43
Catalog No.:BCC6739
CAS No.:145040-29-5
- Candesartan cilexetil
Catalog No.:BCC8900
CAS No.:145040-37-5
- CPI-169
Catalog No.:BCC5396
CAS No.:1450655-76-1
- Rink Amide Linker
Catalog No.:BCC2833
CAS No.:145069-56-3
- YM 022
Catalog No.:BCC7052
CAS No.:145084-28-2
Chlojaponilactone B from Chloranthus japonicus: Suppression of Inflammatory Responses via Inhibition of the NF-kappaB Signaling Pathway.[Pubmed:27588583]
J Nat Prod. 2016 Sep 23;79(9):2257-63.
Bioassay-guided fractionation of an ethanolic extract of Chloranthus japonicus led to the isolation of the known lindenane-type sesquiterpenoid Chlojaponilactone B (1). This compound exhibited pronounced inhibition of nitric oxide (NO) production in lipopolysaccharide (LPS)-induced RAW 264.7 macrophages. Further anti-inflammatory assays showed that 1 suppressed the levels of some key inflammation mediators, such as iNOS, TNF-alpha, and IL-6, in a dose-dependent manner, and reduced the ear thickness and neutrophil infiltration in 12-O-tetradecanoylphorbol-13-acetate (TPA)-stimulated mice. A mechanistic study revealed that compound 1 exerted its anti-inflammatory effects via the suppression of the NF-kappaB signaling pathway, which inhibited NF-kappaB-dependent transcriptional activity, IkappaBalpha phosphorylation, and p65 nuclear translocation. In contrast, Chlojaponilactone B (1) was found to exert little influence on the MAPK signaling pathway.